Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Advanz Pharma
Deal Size : $343.4 million
Deal Type : Partnership
Details : Advanz Pharma secures exclusive rights from Alvotech to commercialize AVT05, a biosimilar candidate to Simponi and Simponi Aria (golimumab), AVT16, a proposed biosimilar to Entyvio (vedolizumab), and three additional early-stage, undisclosed biosimilar c...
Product Name : AVT05
Product Type : Antibody
Upfront Cash : $60.1 million
May 24, 2023
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Advanz Pharma
Deal Size : $343.4 million
Deal Type : Partnership
Lead Product(s) : Vedolizumab
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Fuji Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Alvotech and Fuji Pharma Expand Partnership for Additional Biosimilar Candidate in Japan
Details : The new agreement adds another biosimilar candidate to the partnership between Alvotech and Fuji, first announced in 2018, bringing the total number of proposed biosimilar products that the companies are partnering on to six.
Product Name : AVT16
Product Type : Antibody
Upfront Cash : Undisclosed
February 23, 2022
Lead Product(s) : Vedolizumab
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Fuji Pharma
Deal Size : Undisclosed
Deal Type : Partnership